CMND (Clearmind Medicine) Cash Flow from Financing : $5.11 Mil (TTM As of Jul. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jul. 2024, Clearmind Medicine received $0.10 Mil more from issuing new shares than it paid to buy back shares. It spent $0.01 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.38 Mil on other financial activities. In all, Clearmind Medicine earned $0.47 Mil on financial activities for the three months ended in Jul. 2024.

Clearmind Medicine Cash Flow from Financing Historical Data

The historical data trend for Clearmind Medicine's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Cash Flow from Financing Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Cash Flow from Financing

Get a 7-Day Free Trial

0.45

4.35

0.38

8.43

Clearmind Medicine Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Cash Flow from Financing	Get a 7-Day Free Trial															-0.03	-0.83	5.32	0.15	0.47

Clearmind Medicine Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Clearmind Medicine's Cash from Financing for the fiscal year that ended in Oct. 2023 is calculated as:

	Cash Flow from Financing		(A: Oct. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	8.037	+	0	+	-0.03	+	0	+	0	+	0.427
=	8.43

Clearmind Medicine's Cash from Financing for the quarter that ended in Jul. 2024 is:

	Cash Flow from Financing		(Q: Jul. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0.103	+	0	+	-0.013	+	0	+	0	+	0.38
=	0.47

Cash Flow from Financing for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.11 Mil.

Clearmind Medicine (NAS:CMND) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Clearmind Medicine's issuance of stock for the three months ended in Jul. 2024 was $0.10 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Clearmind Medicine's repurchase of stock for the three months ended in Jul. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Clearmind Medicine's net issuance of debt for the three months ended in Jul. 2024 was $-0.01 Mil. Clearmind Medicine spent $0.01 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Clearmind Medicine's net issuance of preferred for the three months ended in Jul. 2024 was $0.00 Mil. Clearmind Medicine paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Clearmind Medicine's cash flow for dividends for the three months ended in Jul. 2024 was $0.00 Mil. Clearmind Medicine received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Clearmind Medicine's other financing for the three months ended in Jul. 2024 was $0.38 Mil. Clearmind Medicine received $0.38 Mil on other financial activities.

Clearmind Medicine Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

CWY0:Germany

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.